AUTHORS
Emma Groarke, MD, Fernanda Gutierrez-Rodrigues, PhD2, Ruba Shalhoub, MS3, Carrie Diamond4, Rebecca Clark, MD5, Sana Pirzada, MD6, Harshkumar Patel, MD7, Tania R Machado, BSN, RN8, Jennifer Lotter, MS9, Ivana Darden, RN10, Nicholas Chien-Juei Lee, MD11, Kadija Hersi, MD12, Theo Heller, MD13, Colin Wu, PhD14, Neal Stuart Young, MD15, Bhavisha A Patel, MD16
AFFILIATIONS
1 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
2 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
3 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
4 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
5 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
6 NIDDK, National Institutes of Health, Bethesda, Maryland, United States
7 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
8 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
9 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
10 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
11 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
12 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
13 NIDDK, National Institutes of Health, Bethesda, Maryland, United States
14 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
15 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
16 National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
ABSTRACT
Introduction
Telomere biology disorders (TBDs) are caused by pathogenic germline variants (PGV) in telomere-related genes resulting in bone marrow failure, pulmonary and liver disease, and predisposition to hematologic and solid cancer. High-dose danazol (800mg daily) improved hematologic parameters and stabilized telomere length (TL) measured by quantitative PCR (qPCR) in our previous trial (NCT01441037). However, poor drug tolerance lead to early treatment discontinuation in nearly 20% of patients, and more accurate TL measurements techniques are needed to confirm telomere elongation using danazol. In this prospective phase II study (NCT03312400), the primary endpoint was to evaluate the superiority of intermediate versus low dose danazol in reduction of TL attrition rates measured by Flow-FISH.
Methods
Eighteen patients with TL <10th percentile, a PGV in a known TBD gene, and significant cytopenia (Hb <10g/dL, platelets count ≤50,000/μL, or neutrophil count ≤ 1,000/μL), or pulmonary (PF) or hepatic fibrosis (transient elastography [TE] score >10kPa or cirrhosis) were included. Patients were randomized to low (200mg daily, n=8) or intermediate (400mg daily, n=10) dose danazol; after 6 months of therapy, all crossed over to the alternative dose. Response criteria was defined as a 50% reduction of TL attrition rate in lymphocytes over 6 months on drug; attrition rate was established prior to intervention by two TL measurements obtained 6 months apart. Secondary endpoints included: 1) hematologic response if significant cytopenia; 2) change in PF: reduction in rate of force vital capacity decline of 5% predicted difference between baseline rate of decline and rate of decline in FVC on drug; 3) change in hepatic fibrosis: improvement in fibroscan TE of ≥ 20% after 6 and 12 months of treatment; 4) toxicities after 6 and 12 months on danazol. The study was terminated early by the DSMB due to futility.
Results
Median age was 35 (15-72) and PGVs were in TERT (n=10), TERC (n=5), DKC1 (n=1) and PARN (n=2). Most (n=16/18; 89%) had TL <1st percentile for age. Significant cytopenia was present in 12/18 (67%) patients, while PF and liver fibrosis were present in 8/18 (44%) and 5/18 (28%), respectively.
Drug was well tolerated at both doses. Two patients discontinued danazol due to severe drug-induced rash and persistent grade 3 transaminitis; both resolved upon drug cessation. Two other patients stopped drug after 6-months due to non-compliance.
There was no significant difference in rate of TL attrition at 6 months between intermediate-dose (5/10 responders; 50%) and low-dose arms (3/8 responders; 37%). Pre-treatment rate of TL attrition had positive values in 7 patients, consistent with increased TL over 6-months before drug initiation. To overcome the inter-assay variability that may impede interpretation of serial TL results and response criteria, we evaluated whether TL changes >2 reported flow-FISH standard deviation (0.2Kb) remained significant. Applying this criteria, 7 patients still met response criteria (n=4 [low-dose] and n=3[intermediate-dose]). In responders, median change in TL over 6 months was +0.3Kb while in non-responders it was -0.25Kb.
Of 12 patients with cytopenia, 50% responded at 6 months (low- [n=4] or intermediate-dose [n=2]). Response was sustained in all patients after 12 months and there were two additional responders, both in low-dose arm. However, most relapsed (7/8) within 6 months of drug cessation.
In 8 patients with PF, response was achieved in 4 patients (one at 6 months [intermediate-dose], two at 12 months [low and intermediate-dose], and one [low-dose] at 18 months [6 months after drug cessation]). Sustained response off drug was observed in only 1 patient, who had achieved initial response at 6 months.
Among 5 patients with hepatic fibrosis, 3/3 were responders (1 at 6 months and additional 2 at 12 months). The other 2 were non-evaluable due to lack of fibroscan. At 18 months (6 months off therapy), 2/3 maintained response.
Conclusions:
Danazol at low and intermediate-dose was well tolerated. Hematologic response occurred in ~50% at 6 months in both dose levels indicating danazol activity with lower doses; however, relapse is common. Improvement was observed in those with hepatic fibrosis but numbers were low. Reduction of TL attrition was observed, however, given flow-FISH inter-assay variability for serial TL measurements, validation using other techniques is required to confirm our findings.
DISCLOSURES
Emma Groarke, MD: No relevant conflicts of interest to declare.